EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
DON'T BUY

Pfizer Inc(PFE)

Feb 09, 2005
Over a 3/5 year period, it's probably OK, but it's trending down and there's no reason to get in the way of that until it changes direction. There is pricing pressure in the drug industry, product liability questions, cross border shopping , etc.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.05

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Likes this one a lot. Trading at 11 X earnings and a 3% dividend yield and waiting to see if Cellebrex gets FDA OK. Downside is pretty limited.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Big headline risk and he loves stock with headline risks. Trading at a 50% discount to what it's really worth.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 07, 2005
There is no technical sign that the ugliness has changed yet. No real strong support for the stock here. However, long term pharma sector is an interesting play.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 03, 2005
All the drug stocks in the US have dropped, but this had the best performance of all of them. Their Cellebrex has not been pulled and this has created some negatives. 3.2% yield and if it turns out the FDA finds no problem with the drug, it will be a major factor. Selling for 11 X earnings. Good price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$23.91

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 31, 2005
FDA is becoming a lot more stricter with their criteria. Drug companies pipelines are a little bit thin now. A lot of competition. Valuations are cheaper than they've ever been. May not see any gains for a while.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$24.16

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 24, 2005
The industry as a whole has been in a difficult time. A lot of the stuff has been discounted in the stock. Trading at a very cheap multiple. Lots of cash and a high dividend yield. Good long term hold 4/5 years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.26

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 21, 2005
A tough BUY, but given the valuation, if you have a 3/5 year time horizon the positives outweigh the negatives.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$24.48

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 20, 2005
Big pharmas have suffered because generics have come out of nowhere and have moved up to 50% of their business. The shine is coming off these companies and their credibility. Now trading at 12 X earnings and have a ton of cash, so could be buying back shares and improve its dividend. Good yield, but limited growth.
Photo of Ian AinsworthIan Ainsworth
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 20, 2005
Could never understand the love for this stock as it was falling. It may have been oversold enough that it goes back up to $30 in the next 2 months. Long term, not very exciting.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 18, 2005
(A Top Pick Oct 26/04. Down 11%.) About a 50% differential between their model price and its present price. In their top 10. Has great value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.30

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 12, 2005
If you look at what has happened to the pharnaceuticals over the last 2 years, generally the big ethical drug companies have been very poor performers. Growth rates have dropped to low single digits. Prefers bio-tech or bio-pharmaceuticals that have growth.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$26.03

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 05, 2005
Has been hurt by the Cox-2 inhibitor problem which is in their Celbrex and Bextra. Pharmaceutical stocks in general have all been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$26.27

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 24, 2004
(A Top Pick Oct 26/04. Down 8%.) Model price is $39. Totally mispriced. Should be a portion of everybody's portfolio. Looking out a year, you should make good money off it.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 17, 2004
There was a negative call on one of their drugs which affected the stock price dramatically. This will mean a lot more testing and a lot more money. Have other products in their stable they can go with.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 676 to 690 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica